Health

Tempus AI's first profit came with $47.1 million of other income and a fifth of data revenue from Pathos AI

Tempus booked record revenue and its first non-GAAP profit on November 2. The filing behind the headline carries a $47.1 million other-income line, a fifth of data revenue from the CEO's own Pathos AI, and a Personalis vote on November 30.

Vincent JiangVincent Jiangthree-minute read
Share
Eric Lefkofsky, founder and chief executive of Tempus AI, wearing glasses, a white shirt and an orange tie
1 / 7Slide 1 of 7
Eric Lefkofsky, founder and chief executive of Tempus AI, told analysts "this quarter, we made the turn."

Eric Lefkofsky, founder and chief executive of Tempus AI−2.59% — Tempus AI, down 2.59 percent today, told analysts on November 2: "This quarter, we made the turn 13." The company behind that line, a Chicago genomic-testing and data-licensing firm, had just reported record revenue of $411.5 million, up 23%, raised full-year guidance to $1.60–1.605 billion, and booked its first non-GAAP profit: $13.4 million, with adjusted EBITDA of $25.6 million against $1.5 million a year earlier 13. The stock closed at $78.48, up 8.7%, valuing Tempus at about $14.3 billion 4.

The turn, against the GAAP ledger

The audited-basis lines are quieter. Loss from operations improved 7%, to $56.9 million from $61.0 million 2. The net loss narrowed 81% to $14.9 million because other income jumped to $47.1 million from $2.6 million: currency gains, marks on marketable securities, and license income from SB Tempus, its Japanese joint venture 2. Strip that line out and the pretax loss is about $59.6 million 1. The non-GAAP profit, in turn, exists only after excluding $50.8 million of stock compensation 1.

Revenue more than doubled in two years; the operating loss ended where it started

  • Revenue
  • Operating income (GAAP)
-$200M$0M$200M$400M$600MQ3 '24Q1 '25Q3 '25Q1 '26Q3 '26First non-GAAP profit
Data
RevenueOperating income (GAAP)
Q3 '24$180.9M-$53.6M
Q4 '24$200.7M-$50.7M
Q1 '25$255.7M-$68.7M
Q2 '25$314.6M-$61.8M
Q3 '25$334.2M-$61M
Q4 '25$367.2M-$61.4M
Q1 '26$348.1M-$84.7M
Q2 '26$382.5M-$75.9M
Q3 '26$411.5M-$56.9M
Revenue more than doubled in two years; the operating loss ended where it started8,1

A fifth of the data business is the founder's other company

Of $108.1 million in Data and Applications revenue, $22.1 million came from Pathos AI, the drug-development company Lefkofsky co-founded and chairs 2. One dollar in five of the data revenue carrying Tempus's premium multiple was billed to a company its own founder controls.

Pathos owes $200 million in license fees over three years and has settled $17.5 million of them, in two $8.8 million instalments paid in Pathos Series D preferred stock, not cash 2. The arm's-length business is real: Bristol Myers Squibb+0.49% — Bristol Myers Squibb, up 0.49 percent today is paying up to $137.5 million over five years, bookings top $550 million year to date, and related-party revenue actually fell year over year while the segment grew 33% 12. The $55 million Alzheimer's tranche still runs through Pathos, as we reported on October 23 12.

The vote that prices it, four weeks out

Minimal residual disease (MRD) tests, which look for cancer traces after treatment, reached about 12,000 in the quarter, up 300% from roughly 3,000, inside a test book that grew about 13%, to 244,500 12. The assay, NeXT Personal Dx, is made by Personalis, which Tempus agreed on July 20 to buy for $16.25 a share in stock; Personalis holders vote on November 30, and can walk if Tempus's 15-day average price before closing falls below $46 2.

Lefkofsky's own economics warning on the call: "when Personalis runs these tests, they lose money" 3. Jefferies−0.50% — Jefferies, down 0.50 percent as of its last quote set Hold at $70 on November 3, BTIG set $100 56, and at 9.9 times sales against a peer group at 7.8 7, the multiple keeps assuming the arm's-length data arrives on schedule.

Jefferies at $70 and BTIG at $100 bracket the $78.48 close

$0$50$100Jefferies targetClose, Nov 2BTIG target$100$78.48
Data
Price target or close
Jefferies target$70
Close, Nov 2$78.48
BTIG target$100
Jefferies upgraded Tempus to Hold with a $70 target on November 3, BTIG raised its target to $100 the same day, and the stock closed November 2 at $78.48. Sources: Investing.com; Yahoo Finance.5,6,4

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading TEM

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Molina Healthcare's CFO lays out a path to $9.50 EPS in 2027, on $4 of fixes not yet earned

    Molina's finance chief added $4 of "embedded earnings" to a $5.25 floor for 2027, assuming no recovery at all in Medicaid margins. Guidance, and the test of each dollar, arrives in February.

    Health

    Hims & Hers grew revenue 49% to $890 million, lost $33 million, and cut its 2026 profit outlook a third time

    Revenue grew 49% and the quarter still lost money, because selling Lilly's and Novo's branded weight-loss drugs books the full price without keeping it. Hims shareholders are paying for the pivot; Lilly gains a channel it barely needs.

    Health

    ACP licenses its guidelines to OpenEvidence for an undisclosed price

    The largest US medical society's guidance moves into a free, ad-funded AI valued at $15 billion, and neither side named the fee. For listed readers, the test is Wolters Kluwer's UpToDate renewals at February 2027 results.

    Health

    FDA orders NAION vision-loss warning on every GLP-1 label; Novo Nordisk up 2.65%, Eli Lilly up 4.28%

    The FDA's class-wide vision-loss warning on the world's biggest drug franchise rests on ten probable cases against five among placebo patients; Novo Nordisk and Eli Lilly rose on the news, and hundreds of blindness suits now hold a federal exhibit.

    Health

    Eli Lilly will file its obesity pill Foundayo for sleep apnea after a 44% cut in severity

    A 43.8% cut in breathing interruptions gives Lilly's pill a shot at a diagnosed-disease budget, and the company commits to an FDA filing by year-end. Novo Nordisk's rival outcomes strategy failed at the same heart conference.

    Health

    Novo Nordisk's ziltivekimab cut inflammation 76% but not heart outcomes; Novartis's pelacarsen failed too

    Published in the New England Journal of Medicine beside Novartis's identical pelacarsen null, the full results show how far a record biomarker win sits from a clinical outcome. The bill already runs from Novo's DKK 4.6 billion write-down to Ionis, down 28% on Monday.

    Get the newsletter

    The day's AI and market news, in your inbox every weekday.